By Adam L. Cataldo Annovis Bio, a clinical-stage drug platform company based in Berwyn, Pa., recently announced positive findings from an independent statistical group regarding its Phase 2/3 study on Alzheimer's disease. The company revealed that there is no need to include additional patients, allowing the study to continue as planned. Market Reaction and Future … [Read more...] about Promising Results for Annovis Bio’s Phase 2/3 Study on Alzheimer’s Disease
Drug Development
AstraZeneca’s Acquisition of Gene Therapies Portfolio
AstraZeneca PLC (AZN) has recently announced a significant deal, acquiring a portfolio of gene therapies from Pfizer Inc. (PFE) for up to $1 billion. Set to close in the third quarter, this strategic move will provide AstraZeneca with a collection of early-stage gene therapies that specifically target rare diseases. This development holds immense potential as it has the … [Read more...] about AstraZeneca’s Acquisition of Gene Therapies Portfolio
Theseus Pharmaceuticals Terminates Development of THE-630
Shares of Theseus Pharmaceuticals took a significant hit on Friday following the company's announcement that it would be discontinuing the development of THE-630 for patients with gastrointestinal stromal tumors. The decision to terminate development came after the company discovered two dose-limiting toxicities associated with hand-foot skin reaction. As a result, Theseus … [Read more...] about Theseus Pharmaceuticals Terminates Development of THE-630
Moleculin Biotech Announces Positive Results From Phase 1 Clinical Trial of Annamycin
Moleculin Biotech, a clinical stage pharmaceutical company, has reported encouraging data from a Phase 1 clinical trial of their drug, annamycin. The study revealed no evidence of cardiotoxicity in the subjects treated with the drug. As a result, Moleculin Biotech's shares soared by 17% to 72 cents. Despite experiencing a 33% decline in the stock value this year, this recent … [Read more...] about Moleculin Biotech Announces Positive Results From Phase 1 Clinical Trial of Annamycin
